Fulcrum Therapeutics to Participate in Upcoming December Conferences

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced its participation in three major healthcare conferences this December. The company will present at the Piper Sandler 36th Annual Healthcare Conference on December 3 with a fireside chat at 12:00 pm ET in New York, the Citi 2024 Global Healthcare Conference on December 4 in Miami, and the Evercore ISI 7th Annual HealthCONx Conference on December 5 in Miami. The Piper Sandler fireside chat webcast will be available on Fulcrum's website for at least 30 days after the presentation.

News Market Reaction

+11.27%

1 alert

+11.27% News Effect

On the day this news was published, FULC gained 11.27%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:

• Piper Sandler 36^th Annual Healthcare Conference
  December 3, 2024
  Fireside Chat at 12:00 pm ET, Participation link: HERE
  New York, New York

• Citi 2024 Global Healthcare Conference
  December 4, 2024
  Miami, Florida

• Evercore ISI 7th Annual HealthCONx Conference
  December 5, 2024
  Miami, Florida

The webcast of the Piper Sandler fireside chat will be accessible by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcasts will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentations.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

FAQ

What healthcare conferences is Fulcrum Therapeutics (FULC) attending in December 2024?

Fulcrum Therapeutics is attending three conferences: Piper Sandler Healthcare Conference (Dec 3), Citi Global Healthcare Conference (Dec 4), and Evercore ISI HealthCONx Conference (Dec 5).

When is Fulcrum Therapeutics' (FULC) fireside chat at the Piper Sandler conference?

Fulcrum Therapeutics' fireside chat at the Piper Sandler Healthcare Conference is scheduled for December 3, 2024, at 12:00 pm ET in New York.

Where can I watch Fulcrum Therapeutics' (FULC) Piper Sandler presentation?

The webcast can be accessed through the 'Events and Presentations' section of Fulcrum Therapeutics' website at ir.fulcrumtx.com, and will be available for at least 30 days after the presentation.